Endpoints
toxicity, rash, pruritus, paronychia, palmar‐plantar erythrondysesthesia syndrome, eczema
SKIN INFECTION, PARONYCHIA, ERYTHEMA MULTIFORME, SKIN TOXICITIES, ECZEMA
The primary endpoint was the incidence of skin toxicities ranked as Grade ≥2 during the initial 8 weeks of dacomitinib treatment. Dermatologic toxicity was defined as acneiform rash, dry skin, pruritus, paronychia, palmar‐plantar erythrondysesthesia syndrome, maculopapular rash, erythema multiforme, skin infection, and eczema. Secondary endpoints included the incidence of dose reduction of dacomitinib, PFS, and safety.